P53 protein regulates Hsp90 atpase activity and thereby wnt signaling by modulating Aha1 expression

Journal of Biological Chemistry

Volumn 289, Issue 10, 2014, Pages 6513-6525

  Okayama, Sachiyo ^a   Kopelovich, Levy ^a   Balmus, Gabriel ^c   Weiss, Robert S ^c   Herbert, Brittney Shea ^b   Dannenberg, Andrew J ^a   Subbaramaiah, Kotha ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE EXPRESSION;

ATP-ASE ACTIVITY; NEW MECHANISMS; P53 PROTEIN; TARGET GENES; TUMOR SUPPRESSOR GENES; VIA EFFECT; WNT SIGNALING;

SIGNALING;

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ADENOSINE TRIPHOSPHATASE; AHA1 PROTEIN; BETA CATENIN; CHAPERONE; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; EPITHELIUM CELL; FAMILIAL CANCER; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

COLON CANCER; HSP90; P53; WNT PATHWAY; Β-CATENIN;

ADENOSINE TRIPHOSPHATASES; ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LI-FRAUMENI SYNDROME; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; PYRIMIDINES; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84896799669     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.532523     Document Type: Article

References (51)

1. Schneikert, J., and Behrens, J. (2007) The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 56, 417-425
2. Polakis, P. (2000) Wnt signaling and cancer. Genes Dev. 14, 1837-1851
3. Bienz, M., and Clevers, H. (2000) Linking colorectal cancer to Wnt signaling. Cell 103, 311-320
4. Kinzler, K. W., and Vogelstein, B. (1996) Lessons from hereditary colorectal cancer. Cell 87, 159-170
5. Mikels, A. J., and Nusse, R. (2006) Wnts as ligands: processing, secretion and reception. Oncogene 25, 7461-7468
6. Sadot, E., Geiger, B., Oren, M., and Ben-Ze'ev, A. (2001) Down-regulation of catenin by activated p53. Mol. Cell. Biol. 21, 6768-6781
7. Levina, E., Oren, M., and Ben-Ze'ev, A. (2004) Down-regulation of catenin by p53 involves changes in the rate of catenin phosphorylation and Axin dynamics. Oncogene 23, 4444-4453
8. Kim, N. H., Kim, H. S., Kim, N. G., Lee, I., Choi, H. S., Li, X. Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., Park, C., Kim, K., Lee, S., Gumbiner, B. M., Yook, J. I., and Weiss, S. J. (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci. Signal. 4, ra71
9. Muller, P. A., and Vousden, K. H. (2013) p53 mutations in cancer. Nat. Cell Biol. 15, 2-8
10. Gaglia, G., Guan, Y., Shah, J. V., and Lahav, G. (2013) Activation and control of p53 tetramerization in individual living cells. Proc. Natl. Acad. Sci. U.S.A. 110, 15497-15501
11. Vousden, K. H., and Prives, C. (2009) Blinded by the light: the growing complexity of p53. Cell 137, 413-431
12. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307-310
13. Soussi, T., Ishioka, C., Claustres, M., and Béroud, C. (2006) Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat. Rev. Cancer 6, 83-90
14. Herbert, B. S., Chanoux, R. A., Liu, Y., Baenziger, P. H., Goswami, C. P., Mc-Clintick, J. N., Edenberg, H. J., Pennington, R. E., Lipkin, S. M., and Kopelovich, L. (2010) A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget 1, 405-422
15. Donehower, L. A., Godley, L. A., Aldaz, C. M., Pyle, R., Shi, Y. P., Pinkel, D., Gray, J., Bradley, A., Medina, D., and Varmus, H. E. (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 9, 882-895
16. Athar, M., Elmets, C. A., and Kopelovich, L. (2011) Pharmacological activation of p53 in cancer cells. Curr. Pharm. Des. 17, 631-639
17. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. U.S.A. 89, 4495-4499
18. Zhao, R., Gish, K., Murphy, M., Yin, Y., Notterman, D., Hoffman,W.H., Tom, E., Mack, D. H., and Levine, A. J. (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14, 981-993
19. Shay, J. W., Tomlinson, G., Piatyszek, M. A., and Gollahon, L. S. (1995) Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol. Cell. Biol. 15, 425-432
20. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275
21. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
22. Ali, J. A., Jackson, A. P., Howells, A. J., and Maxwell, A. (1993) The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry 32, 2717-2724
23. Mohebati, A., Guttenplan, J. B., Kochhar, A., Zhao, Z. L., Kosinska, W., Subbaramaiah, K., and Dannenberg, A. J. (2012) Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. Cancer Prev. Res. 5, 593-602
24. Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., and Weinberg, R. A. (1994) Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7
25. Taipale, M., Jarosz, D. F., and Lindquist, S. (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11, 515-528
26. Zhang, H., and Burrows, F. (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82, 488-499
27. Garcia-Carbonero, R., Carnero, A., and Paz-Ares, L. (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 14, e358-e369
28. Kurashina, R., Ohyashiki, J. H., Kobayashi, C., Hamamura, R., Zhang, Y., Hirano, T., and Ohyashiki, K. (2009) Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 284, 62-70
29. Maloney, A., and Workman, P. (2002) HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2, 3-24
30. He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y., Wu, N., Immormino, R. M., Gewirth, D. T., and Chiosis, G. (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein. J. Med. Chem. 49, 381-390
31. Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J. K., Singh, S., Millson, S. H., Clarke, P. A., Naaby-Hansen, S., Stein, R., Cramer, R., Mollapour, M., Workman, P., Piper, P. W., Pearl, L. H., and Prodromou, C. (2002) Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1. Mol. Cell 10, 1307-1318
32. Retzlaff, M., Hagn, F., Mitschke, L., Hessling, M., Gugel, F., Kessler, H., Richter, K., and Buchner, J. (2010) Asymmetric activation of the Hsp90 dimer by its cochaperone Aha1. Mol. Cell 37, 344-354
33. Lotz, G. P., Lin, H., Harst, A., and Obermann, W. M. (2003) Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J. Biol. Chem. 278, 17228-17235
34. Holmes, J. L., Sharp, S. Y., Hobbs, S., and Workman, P. (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17- demethoxygeldanamycin. Cancer Res. 68, 1188-1197
35. Sato, S., Fujita, N., and Tsuruo, T. (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. U.S.A. 97, 10832-10837
36. Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., and Rosen, N. (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277, 39858-39866
37. Anderson, E. C., and Wong, M. H. (2010) Caught in the Akt: regulation of Wnt signaling in the intestine. Gastroenterology 139, 718-722
38. Nakayama, M., Hisatsune, J., Yamasaki, E., Isomoto, H., Kurazono, H., Hatakeyama, M., Azuma, T., Yamaoka, Y., Yahiro, K., Moss, J., and Hirayama, T. (2009) Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. J. Biol. Chem. 284, 1612-1619
39. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W., and Chang, E. H. (1990) Germ line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747-749
40. Evans, D. G., Birch, J. M., Thorneycroft, M., McGown, G., Lalloo, F., and Varley, J. M. (2002) Low rate of TP53 germ line mutations in breast cancer/ sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J. Med. Genet. 39, 941-944
41. Li, J., Soroka, J., and Buchner, J. (2012) The Hsp90 chaperone machinery: conformational dynamics and regulation by co-chaperones. Biochim. Biophys. Acta 1823, 624-635
42. Cox, M. B., and Johnson, J. L. (2011) The role of p23, Hop, immunophilins, and other co-chaperones in regulating Hsp90 function. Methods Mol. Biol. 787, 45-66
43. Chen, Y., Chen, J., Loo, A., Jaeger, S., Bagdasarian, L., Yu, J., Chung, F., Korn, J., Ruddy, D., Guo, R., McLaughlin, M. E., Feng, F., Zhu, P., Stegmeier, F., Pagliarini, R., Porter, D., and Zhou, W. (2013) Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget 4, 816-829
44. Swick, L., and Kapatos, G. (2006) A yeast 2-hybrid analysis of human GTP cyclohydrolase I protein interactions. J. Neurochem. 97, 1447-1455
45. Chen, D. D., Zhao, T., Li, J., and Chen, A. F. (2011) GTP cyclohydrolase I rescues microRNA-34a impairment of endothelial progenitor cell angiogenesis in aging. Circulation 124, A17288
46. Rao, C. V., Swamy, M. V., Patlolla, J. M., and Kopelovich, L. (2008) Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/mice. Cancer Res. 68, 7670-7675
47. Wong, P., Verselis, S. J., Garber, J. E., Schneider, K., DiGianni, L., Stockwell, D. H., Li, F. P., and Syngal, S. (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130, 73-79
48. Ruijs, M. W., Verhoef, S., Rookus, M. A., Pruntel, R., van der Hout, A. H., Hogervorst, F. B., Kluijt, I., Sijmons, R. H., Aalfs, C. M., Wagner, A., Ausems, M. G., Hoogerbrugge, N., van Asperen, C. J., Gomez Garcia, E. B., Meijers-Heijboer, H., Ten Kate, L. P., Menko, F. H., and van 't Veer, L. J. (2010) TP53 germ line mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J. Med. Genet. 47, 421-428
49. Maloney, A., Clarke, P. A., and Workman, P. (2003) Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr. Cancer Drug Targets 3, 331-341
50. Armstrong, H., Wolmarans, A., Mercier, R., Mai, B., and LaPointe, P. (2012) The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922. PLoS One 7, e49322
51. Zurawska, A., Urbanski, J., Matuliene, J., Baraniak, J., Klejman, M. P., Filipek, S., Matulis, D., and Bieganowski, P. (2010) Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. Biochim. Biophys. Acta 1803, 575-583